Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far
Pivotal Trial Likely To Include Consolidation Dosing
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
